Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns | GenomeWeb

Roche made a splash last year with its repeated overtures to acquire genome sequencing firm Illumina, but for the most part, 2012 was a quiet year during which players in the life sciences industry took modest steps to increase their capabilities to advance personalized treatments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.